Merck (MRK) said Tuesday that Health Canada has granted approval for Keytruda as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non-small cell lung carcinoma.
The approval is for Keytruda to be administered in combination with platinum-containing chemotherapy as neoadjuvant treatment and as a monotherapy for adjuvant treatment after surgery, Merck said.
The company said the approval was based on the results of a phase 3 trial, where Keytruda demonstrated "statistically significant" results for the primary endpoints of event-free survival and overall survival.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。